Background: Increasing chronic diseases challenges the health systems of low- and middle-income countries, including Cameroon. Type 1 diabetes (T1D), among the most common chronic diseases in children, poses particular care delivery challenges.
Aim: We examined social representations of patients' roles and implementation of T1D care among political decision-makers, healthcare providers and patients within families.
Setting: The study was conducted in Yaoundé, Cameroon.
Methods: Eighty-two individuals were included in the study. The authors conducted semi-structured interviews with policy makers (n = 5), healthcare professionals (n = 7) and patients 'parents (n = 20). Questionnaires were administered to paediatric patients with T1D (n = 50). The authors also observed care delivery at a referral hospital and at a T1D-focused non-governmental organisation over 15 days. Data were analysed using thematic content analysis and descriptive statistics.
Results: Cameroonian health policy portrays patients with T1D as passive recipients of care. While many practitioners recognised the complex social and economic determinants of adherence to T1D care, in practice interactions focused on specific biomedical issues and offered brief guidance. Cultural barriers and policy implementation challenges prevent patients and their families from being fully active participants in care. Parents and children prefer an ongoing relationship with a single clinician and interactions with other patients and families.
Conclusion: Patients and families mobilise experience and lay knowledge to complement biomedical knowledge, but top-down policy and clinical practice limit their active engagement in T1D care.Contribution: Children with T1D and their families, policy makers, healthcare professionals, and civil society have new opportunities to contribute to person-centred care, as advocated by the Sustainable Development Goals.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11019050 | PMC |
http://dx.doi.org/10.4102/phcfm.v16i1.4229 | DOI Listing |
Alzheimers Dement
December 2024
Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of Washington, Seattle, WA, USA; VA Puget Sound Health Care System, Seattle, WA, USA.
Background: Incretin receptor agonists (IRAs) are synthetic peptides that have beneficial effects within the brain. We investigated IRA brain uptake following two routes of delivery: across the blood-brain barrier (BBB) and following intranasal (IN) delivery.
Method: Radiolabeled IRAs were delivered intravenously or intranasally into CD-1 mice and uptake by or distribution throughout the brain was assessed.
Alzheimers Dement
December 2024
School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar, Punjab, India.
Background: Alzheimer's disease (AD) is a type of degenerative disorder that affects the brain. There are various herbal drugs that have been tested for their effectiveness in treating AD, and chrysin is one of them. Chrysin is a polyphenolic flavonoid that has several neuroprotective effects, including reducing the levels of AChE enzyme, accumulated amyloid β, oxidative stress, and neuroinflammation.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Faculty of Health, University of Canberra, Bruce, ACT, Australia.
Background: There is a need to understand the benefits and limitations of innovative models of dementia care to ensure models meet the needs of people living with dementia, their families and staff. The aim of this scoping review was to explore and synthesise the barriers and facilitators to the widespread implementation of small-scale residential dementia care.
Method: A scoping review was conducted in 2023 in MEDLINE, CINAHL, PsycINFO, Scopus, Web of Science, and CENTRAL to identify empirical, peer-reviewed studies, published in English from database inception to October 2023.
Alzheimers Dement
December 2024
University College London, London, United Kingdom.
Background: The progressive nature of dementia and the complex needs means that people living with dementia require tailored approaches to address their changing care needs over time. These include physical multimorbidity, psychological, behavioural, and cognitive symptoms and possible risks arising from these and helping family caregivers. However, provision of these interventions is highly variable between and within countries, partly due to uncertainty about their efficacy and scarce resources.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!